Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tianjin Pharmaceutical Da Ren Tang GroupSTU:2TZ 71 Return-on-Tangible-Asset is 16.05% as of Mar. 2026, which is 82% above its 10-year median of 8.83. GuruFocus rates STU:2TZ with a GF Score™ of 71/100 and a GF Value™ of €1.65 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,009 Drug Manufacturers companies, Tianjin Pharmaceutical Da Ren Tang Group ranks better than 93.56% on this metric.
STU:2TZ'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.98 Med: 8.83 Max: 22.02
Current: 19.44
During the past 13 years, Tianjin Pharmaceutical Da Ren Tang Group's highest Return-on-Tangible-Asset was 22.02%. The lowest was 6.98%. And the median was 8.83%.
STU:2TZ's Return-on-Tangible-Asset is ranked better than 93.56% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.08
vs STU:2TZ: 19.44
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Tianjin Pharmaceutical Da Ren Tang Group Return-on-Tangible-Asset Related Terms
Tianjin Pharmaceutical Da Ren Tang Group Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group Return-on-Tangible-Asset Chart
Tianjin Pharmaceutical Da Ren Tang Group Annual Data
STU:2TZ vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 16.05% mean?
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) has a Return-on-Tangible-Asset of 16.05% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. This is 82% above median its historical median of 8.83. Over the past decade, Tianjin Pharmaceutical Da Ren Tang Group's Return-on-Tangible-Asset has ranged from 6.98 to 22.02. According to the industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #65 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 6.4%.
Is Tianjin Pharmaceutical Da Ren Tang Group's Return-on-Tangible-Asset too high?
Tianjin Pharmaceutical Da Ren Tang Group's current Return-on-Tangible-Asset of 16.05% is 82% above median its 10-year median of 8.83. Over the past 10 years, this metric has ranged from a low of 6.98 to a high of 22.02. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.08. Tianjin Pharmaceutical Da Ren Tang Group's value of 16.05% is 421.1% above this industry median. Based on the distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #65 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #65 out of 1009 companies for Return-on-Tangible-Asset. This places Tianjin Pharmaceutical Da Ren Tang Group in the top 6% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.08. Tianjin Pharmaceutical Da Ren Tang Group's value of 16.05% is 421.1% above this benchmark. Historically, Tianjin Pharmaceutical Da Ren Tang Group's own Return-on-Tangible-Asset has ranged from 6.98 to 22.02 over the past decade. While the company's 10-year median is 8.83 vs. the industry median of 3.08, Tianjin Pharmaceutical Da Ren Tang Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.08, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin Pharmaceutical Da Ren Tang Group's current Return-on-Tangible-Asset of 16.05% is 421.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin Pharmaceutical Da Ren Tang Group's current Return-on-Tangible-Asset is 16.05%, which is 82% above median its own 10-year median of 8.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.65, compared to a current price of €2.40 — trading 45.5% above its estimated fair value. The current Return-on-Tangible-Asset is 16.05%, which is 82% above median its 10-year median of 8.83 and 421.1% above the Drug Manufacturers industry median of 3.08. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ), the current Return-on-Tangible-Asset is 16.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued.
The current stock price of €2.40 is trading 45.5% above its estimated GF Value™ of €1.65.
GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.
Key valuation signals for STU:2TZ:
Return-on-Tangible-Asset: 16.05% (82% above median its 10-year median of 8.83)
GF Value™: €1.65 vs. price of €2.40 (45.5% above fair value)
Industry Position: 421.1% above the Drug Manufacturers median (#65 of 1009)
No single metric tells the full story. See the STU:2TZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
71GF Score
Get the complete analysis for STU:2TZ
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2TZ has been successfully added to your 
